UnitedHealthcare Pharmacy
Clinical Pharmacy Programs
Program Number 2025 P 1027-13
Program Prior Authorization/Notification
Medication Egrifta SV™ (tesamorelin for injection)
P&T Approval Date 5/2011, 5/2012, 5/2013, 4/2014, 4/2015, 2/2016, 2/2017, 2/2018, 2/2019,
2/2020, 2/2021, 2/2022, 2/2023, 2/2024, 2/2025
Effective Date 5/1/2025
1. Background:
Egrifta SV (tesamorelin) is a growth hormone releasing factor (GHRF) analog indicated for the
reduction of excess abdominal fat in HIV-infected patients with lipodystrophy.
Limitations of Use:
• Long-term cardiovascular safety of Egrifta SV has not been established.
• Not indicated for weight loss management.
• There are no data to support improved compliance with anti-retroviral therapies in HIV-positive
patients taking Egrifta.
Coverage for Egrifta will be provided for patients who meet the following criteria:
2. Coverage Criteriaa:
A. Initial Authorization
1. Egrifta will be approved based on the following criterion:
a. Diagnosis of HIV-associated lipodystrophy
Authorization will be issued for 12 months.
B. Reauthorization
1. Egrifta will be approved based on the following criterion:
a. Documentation of positive clinical response (e.g., improvement in visceral adipose
tissue [VAT], decrease in waist circumference, belly appearance) while on Egrifta
therapy.
Authorization will be issued for 12 months.
a State mandates may apply. Any federal regulatory requirements and the member specific benefit
plan coverage may also impact coverage criteria. Other policies and utilization management
programs may apply.
© 2025 UnitedHealthcare Services, Inc.
1
3. Additional Clinical Rules:
• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization
based solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic.
Use of automated approval and re-approval processes varies by program and/or therapeutic class.
• Supply limits may be in place.
4. References:
1. Egrifta [prescribing information]. Montreal, Quebec, Canada: Theratechnologies, Inc.; February
2024.
Program Prior Authorization/Notification – Egrifta (tesamorelin for injection)
Change Control
4/2014 Annual review with age assessment resulting in no change in clinical
coverage. Updated references.
4/2015 Annual review with no change in clinical coverage. Updated references.
2/2016 Annual review. Modified initial coverage criteria to require only a
diagnosis. Updated references.
2/2017 Annual review. No change in clinical coverage.
2/2018 Annual review. No change in clinical coverage.
2/2019 Annual review. No change in clinical coverage.
2/2020 Annual review. Updated reauthorization duration to 12 months.
2/2021 Annual review. No changes to clinical coverage. Updated background and
references.
2/2022 Annual review. No changes to clinical coverage.
2/2023 Annual review with no changes to coverage criteria. Updated background,
references and added state mandate footnote.
2/2024 Annual review with no changes to coverage criteria.
2/2025 Annual review. Updated initial authorization to 12 months and updated
reference.
© 2025 UnitedHealthcare Services, Inc.
2